GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Forward PE Ratio
中文

Prenetics Global (Prenetics Global) Forward PE Ratio : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Forward PE Ratio?

Prenetics Global's Forward PE Ratio for today is 0.00.

Prenetics Global's PE Ratio without NRI for today is 0.48.

Prenetics Global's PE Ratio for today is 0.00.


Prenetics Global Forward PE Ratio Historical Data

The historical data trend for Prenetics Global's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Forward PE Ratio Chart

Prenetics Global Annual Data
Trend
Forward PE Ratio

Prenetics Global Quarterly Data
Forward PE Ratio

Competitive Comparison of Prenetics Global's Forward PE Ratio

For the Diagnostics & Research subindustry, Prenetics Global's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Forward PE Ratio falls into.



Prenetics Global Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Prenetics Global  (NAS:PRE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Prenetics Global Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.